InVivo Therapeutics Holdings Corp. (NVIV): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVIV Stock Price Chart Interactive Chart >
NVIV Price/Volume Stats
| Current price | $4.86 | 52-week high | $23.19 |
| Prev. close | $4.83 | 52-week low | $3.50 |
| Day low | $4.80 | Volume | 7,100 |
| Day high | $4.90 | Avg. volume | 21,463 |
| 50-day MA | $6.32 | Dividend yield | N/A |
| 200-day MA | $11.45 | Market Cap | 6.76M |
InVivo Therapeutics Holdings Corp. (NVIV) Company Bio
InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 and is based in Cambridge, Massachusetts.
Latest NVIV News From Around the Web
Below are the latest news stories about Invivo Therapeutics Holdings Corp that investors may wish to consider to help them evaluate NVIV as an investment opportunity.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Drops -488.24% From Highs, What Happens Next?InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)s traded shares stood at 0.71 million during the last session, with the companys beta value hitting 1.01. At the close of trading, the stocks price was $0.34, to imply a decrease of -7.43% or -$0.02 in intraday trading. The NVIV shares 52-week high remains $2.00, putting it -488.24% down since InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Drops -488.24% From Highs, What Happens Next? Read More » |
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect ConferenceCAMBRIDGE, Mass., January 06, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming virtual H.C. Wainwright BioConnect Conference, which runs from January 10 – 13, 2022. Dr. Toselli’s presentation will provide an overview of the company and will also highlight |
Is Now A Good Time To Invest In InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV)?InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 10.97% to the previous days close as strong demand from buyers drove the stock to $0.56. Actively observing the price movement in the last trading, the stock closed the session at $0.50, falling within a range of Is Now A Good Time To Invest In InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV)? Read More » |
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment ConferenceCAMBRIDGE, Mass., September 09, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a virtual format. |
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury StudyCAMBRIDGE, Mass., September 08, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designe |
NVIV Price Returns
| 1-mo | -8.82% |
| 3-mo | -31.98% |
| 6-mo | -64.40% |
| 1-year | -71.09% |
| 3-year | -99.38% |
| 5-year | -99.99% |
| YTD | -57.38% |
| 2021 | -43.69% |
| 2020 | -87.99% |
| 2019 | -85.11% |
| 2018 | -92.16% |
| 2017 | -81.67% |
Loading social stream, please wait...